Onco-hematology
We provide unique expertise to pharmaceutical, biotech companies, and research institutions who wish to evaluate in vitro and in vivo the clinical potential of drug candidates for
Hematological Malignancies
In vitro exploration
|
Evaluation of therapeutic potential of compounds in MM and MCL Cell Lines
Dissection of cellular mechanisms induced by compounds
Identification of the best combination with approved drugs
|
 |
Our cell lines are characterized for:
- Response to conventional and innovative therapeutic agents
- Global gene expression profile
- Whole exome sequencing
- …
In vitro assays available as standard – others upon request
- Cell survival assay (MTT assay, CellTiterGlo assay…)
- Cell proliferation assay (Alamar Blue assay, Thymidine assay…)
- Clonogenic growth assay
- Cell death assay cytometry (Annexin V assay, Apo2.7 assay, Caspase assay)
- Cellular mechanisms (qPCR, Western Blot analysis…)
- Antibodies effectiveness (ADCC assay, CDC assay)
- Custom cell based assays
In vitro Models
- A collection of Multiple Myeloma (MM) Cell Lines (n=30)
- A collection of Mantle Cell Lymphoma (MCL) Cell Lines (n=10)
- Primary Hematologic cancer cells (coming soon)
In vivo exploration
Evaluation of therapeutic potential in xenograft models
- Assessment of drug efficacy using a panel of xenograft MM mouse models recapitulating the MM heterogeneity in immunodeficient mice
- Mouse models development for hematologic cancers
In vivo follow-up, end-points and characterization of drug efficacy:
- Tumor volume measurement
- Monitoring clinical parameters (health status, behavior monitoring, reaction of treatment, weight evolution…)
- Samples for subsequent studies (e.g. serum, blood, tumor tissue)
- Tumor tissue analysis (Western Blot, qPCR)
|
In vivo Models
|
 |
